We evaluated, using in vitro cellular models, the ability of different classes of drugs currently used in IBD to counteract two pivotal processes of intestinal fibrosis, including the differentiation of intestinal fibroblasts to activated myofibroblasts using the CCD-18Co cell line, and the epithelial-to-mesenchymal transition (EMT) of intestinal epithelial cells using the Caco-2 cell line (IEC), with both processes induced by TGF-β1. This evidence concerns the gene TGFB1 and inflammatory bowel disease.